73 results about "Hypersensitivity reaction" patented technology

Tree pollen allergy is seasonal allergy caused by various tree pollen spread in air. The allergy affects a substantial proportion of populations, is particularly significant in European and North America areas, and is characterized by symptoms such as sneezing, nasal obstruction, rhinorrhea, eye itching and lacrimation, and throat irritation. The symptoms typically occur in spring, at which birch, alder, hazel and oak release pollen into the air. Tree pollen allergy is a type 1 hypersensitivity reaction mediated by an immunoglobulin E (IgE) antibody. The present invention relates to antibodies and antigen binding fragments thereof that bind to one or more of tree pollen allergens Bet v 1, Aln g 1, Cor a 1 and Quue a 1, resulting in inhibition of IgE-mediated anaphylaxis.

The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.

The present invention discloses a VHH chain of an anti-APP nanobody and its application. The anti-APP nanobody of the present invention has the following beneficial effects: (1) small molecule and drug delivery. (2) easy to manufacture and express. (3) high affinity and strong specificity. (4) stable performance and good plasticity. (5) low immunogenicity and good metabolic characteristics. The APP nanobody of the present invention retains the ability of the VVH chain antibody and avoids the introduction of non-human exogenous proteins as much as possible, taking into account the function of effectively binding to anti-APP and the lowest possible heterology. In addition, the reduction of heterology can not only reduce hypersensitivity reactions but also prolong its half-life in the body and improve metabolic characteristics.

Tree pollen allergy is a seasonal allergy caused by various tree pollens suspended in the air. This allergy affects a significant proportion of the population, particularly in Europe and North America, and is characterized by symptoms such as sneezing, nasal congestion, runny nose, itchy or watery eyes, and throat inflammation. These symptoms typically occur in spring when trees such as birch, alder, hazel, and oak release pollen into the air. Tree pollen allergy is a type 1 hypersensitivity reaction mediated by immunoglobulin E (IgE) antibodies. This invention relates to antibodies and their antigen-binding fragments that bind to one or more tree pollen allergens, Bet v 1, Aln g 1, Cor a 1, and Que a 1, and inhibit the IgE-mediated allergic reaction.

In some embodiments, a composition comprising Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus plantarum, and Streptococcus thermophilus is provided. In some embodiments, provided is the use of a composition of any of the examples herein for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorder (ASD), anxiety disorder and / or gastrointestinal (GI) disorder or condition, enhancing attention and / or concentration, or stimulating a GABA receptor in a subject. In some embodiments, methods and kits are provided for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorders, anxiety disorders, and / or gastrointestinal disorders or conditions, enhancing attention and / or concentration, or stimulating GABA receptors in a subject. In certain embodiments, the compositions are safe to use and effective to prevent or alleviate anxiety and / or sensory hypersensitivity in subjects, particularly children subjects.

The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.

The present invention refers to a composition including fermented supernatant of Lactobacillus casei or paracasei species. The species is characterized by having in its DNA genome at least one DNA sequence essentially identical to one of the sequences selected from the group consisting of: SEQ ID NO: 1 to 5, and proper diluents and / or carriers and / or excipients. The composition can be used in the treatment and / or prevention of skin and / or dermatological diseases related to inflammation, allergic reactions, contact hypersensitivity reactions and intolerance, excessive sebaceous secretion, exfoliation or microbial dysbiosis, preferably of the epidermis.

Provided are methods of biasing a response of a vaccine recipient's immune system toward protective sensitization. Methods include administering an agent or substance to the site of a subject of a temporally interacting cell-mediated allergic reaction to enhance the resulting level of protective sensitization.

The invention belongs to the field of nursing science, and particularly relates to an acute exacerbation malnutrition risk prediction model for an old chronic obstructive pulmonary disease patient and a construction method of the acute exacerbation malnutrition risk prediction model, which are used for establishing a rapid and accurate prediction model for acute exacerbation malnutrition risk screening and evaluation of the old chronic obstructive pulmonary disease patient. The invention discloses a model for predicting the risk of acute exacerbation dystrophy of an old chronic obstructive pulmonary disease patient. The risk prediction model is a multivariate Logistic regression model: P =-12.845 + 1.022 * age + 0.339 * ethnic + 0.077 * educated degree + 0.683 * gastrointestinal tract symptom + 0.035 * height-0.126 * body mass index + 1.045 * partial pressure of carbon dioxide-0.077 * chloride ion-0.017 * serum albumin-0.004 * prealbumin + 0.005 * hypersensitive C reaction protein + 0.479 * lymphocyte number. According to the acute exacerbation malnutrition risk prediction model for the patient with the chronic obstructive pulmonary disease of the aged and the construction method thereof, the prediction model for rapidly and accurately screening and evaluating the acute exacerbation malnutrition risk of the patient with the chronic obstructive pulmonary disease of the aged is established.

The invention provides pediococcus acidilactici with functions of improving emotion and intestinal health and application of the pediococcus acidilactici. The pediococcus acidilactici A25-4 is preserved in Guangdong Microbial Culture Collection Center on May 23, 2025, and the preservation number of the pediococcus acidilactici A25-4 is GDMCC NO: 66384. The pediococcus acidilactici A25-4 has better cholate resistance and artificial gastrointestinal fluid resistance and can produce indole lactic acid ILA at high yield, and the optimal carbon source is fructo-oligosaccharide and galactooligosaccharide. The pediococcus acidilactici A25-4 in-vivo intervention can significantly improve the symptoms of an irritable bowel syndrome model mouse, specifically, the anxiety mood of a tested object is significantly improved; the viscera hypersensitivity of a tested object is obviously relieved; excessive activation of mast cells of a tested object is obviously inhibited; the ILA level in a tested object is obviously improved.

The invention belongs to the field of marker detection, and particularly relates to a marker for diagnosing or identifying potential causes of migraine, application, a kit, a device and an evaluation model. The invention provides a marker for diagnosing or identifying potential causes of migraine. The marker comprises indoleacrylic acid and / or hypersensitive C-reactive protein. The invention reveals that PFO is combined with migraine metabonomics maps, and branched chain amino acid metabolism, neurosteroid metabolism and tryptophan metabolism disorder are core pathological mechanisms for the first time. On the basis of plasma metabonomics characteristics of a PFO-combined migraine patient and a healthy control, 211 metabolites with significant difference are screened out, it is found that various metabolites are significantly related to the symptom severity of migraine, and two factors [indoleacrylic acid and hypersensitive C-reactive protein (hs-CRP)] significantly related to migraine related to patent foramen ovale are confirmed. In addition, the concentration of indolecrylic acid (IA) is found to have a relatively good prediction value on symptom relief after occlusion.

The invention belongs to the field of forensic detection, and particularly relates to a method for detecting allergens in drug-induced allergic shock. Based on a type I hypersensitivity reaction mechanism, carboxylated microspheres are used for cross-linking an anti-IgE antibody, an IgE-allergen compound in a sensitization stage of a detection sample is combined and captured, interference of residual components of the sample is removed through multiple times of cleaning, the antibody and drug binding protein are digested by enzyme to dissociate drug components, and the immunogenicity of the IgE-allergen compound in the sensitization stage of the detection sample is improved. And the LC-MS is used for qualitatively detecting medicine components so as to achieve the purpose of detecting the medicine allergen.

The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.

The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and / or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and / or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.

Provided are a compound for treating or preventing hypersensitivity or autoimmune inflammation-related diseases, and the use and a method for treating or preventing the hypersensitivity or autoimmune inflammation-related diseases in a subject. The compound is a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof.

The present invention discloses an interfering RNA of TPPP3 and its application, belonging to the field of biomedicine preparation technology. The present invention discloses the application of a preparation for inhibiting TPPP3 in the preparation of a drug for treating type I hypersensitivity reaction, the preparation comprising an siRNA that interferes with the expression of TPPP3, and the nucleotide sequence of the siRNA is as shown in SEQ ID NO: 5-6. The present invention knocks down the TPPP3 gene by RNAi technology, and finds that downregulating the expression of the TPPP3 gene can significantly inhibit IgE-mediated mast cell degranulation, and reduces the activity of upstream signal molecules of the FcεRI signaling pathway to regulate type I hypersensitivity reaction, providing an experimental basis and scientific basis for revealing the pathogenesis of type I hypersensitivity reaction and in-depth research on the role of TPPP3 in type I hypersensitivity reaction.

Provided are compositions and methods of treatment of allergic disorders and other hypersensitivity disorders including allergic rhinitis. For instance, provided is a method of treating a subject afflicted with an allergic disorder or a hypersensitivity disorder comprising administering to the subject a therapeutically effective amount of an antihistamine, a therapeutically effective amount of a corticosteroid and a therapeutically effective amount of a nasal decongestant, for at least four days, thereby treating the subject.

This invention belongs to the field of genetic engineering technology, specifically relating to the application of the AtHIR4 gene and / or its encoded protein in regulating plant pathogen resistance. The amino acid sequence of the protein encoded by the AtHIR4 gene described in this invention is shown in SEQ ID No. 1. This invention created transgenic Arabidopsis and rapeseed expressing hypersensitivity response-inducible protein 4 (AtHIR4). In the AtHIR4 transgenic Arabidopsis, the chitin-activated ROS burst and phosphorylation of MAPKs were significantly enhanced. Disease resistance test results showed that the AtHIR4 transgenic plants not only exhibited enhanced resistance to the necrotrophic pathogens *Sclerotinia sclerotiorum* and *Botrytis cinerea*, but also significantly increased resistance to the semi-vitrotrophic pathogen *Pseudomonas syringae*. The AtHIR4 transgenic rapeseed also showed significantly enhanced resistance to *Sclerotinia sclerotiorum* and *Botrytis cinerea*.

The present invention refers to a composition including a fermented supernatant of Lactobacillus casei or paracasei species The species is characterized by having in its DNA genome at least one DNA sequence essentially identical to one of the sequences selected from the group consisting of: SEQ ID No 1 to 5, and proper diluents and / or carriers and / or excipients. The compositions can be used in the treatment and / or prevention of skin and / or dermatological diseases related to inflammation, allergic reactions, contact hypersensitivity reactions and intolerance, excessive sebaceous secretion, exfoliation or microbial dysbiosis, preferably of the epidermis.

This invention belongs to the field of biopharmaceuticals, specifically relating to an endoplasmic reticulum-targeting antioxidant nanozyme, its preparation method, and its applications. The novel antioxidant nanozyme (Arg-Mnzyme) provided by this invention can effectively inhibit NOX1 expression, eliminate the accumulation of reactive oxygen species, and inhibit NOX1 activation and oxidative stress after temporomandibular joint arthritis-related pain, thus alleviating pain hypersensitivity. Compared to natural enzymes, nanozymes have stronger modifiability; this invention will construct an endoplasmic reticulum-precise antioxidant nanozyme to achieve precise regulation of oxidative stress.

This disclosed technology relates to a new mRNA COVID-19 vaccine that is stable at room temperature, requires only one injection, and is less prone to patient hypersensitivity reactions. The vaccine is practical to deploy globally during vaccination campaigns for current and future coronavirus pandemics and other infectious diseases. The disclosed technology is a method and system for producing the vaccine, and also a double-encapsulated mRNA vaccine product. The method uses double nanoencapsulation of an mRNA vaccine, first in phospholipid nanosomes and then in biodegradable polymer nanospheres. The method may be carried out as a continuous flow, integral, or two-stage processes. The method and system use supercritical fluid technology for nanoencapsulating mRNA in a solvent free process that minimizes loss of potency and preserves antigenicity of the nanoencapsulated mRNA and eliminates residual organic solvents in the final product. The double-encapsulated mRNA vaccine product is stable at room temperature and can be administered in a single shot to humans.

Disclosed is L-asparagine aminohydrolase and polyethylene glycol conjugate. The polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate has a high level of in vitro activity and an unexpected increase in half-life in vivo. Methods of producing the conjugate and methods of using the conjugate in therapy in treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). The method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.

The invention discloses an immune receptor-single-chain antibody fusion protein and application of the immune receptor-single-chain antibody fusion protein in prevention and treatment of potato virus Y (pota virus Y, PVY) and tomato brown fruit ruffle virus (ToBRFV), and belongs to the technical field of biological prevention and treatment of viral diseases. According to the invention, a modified immune receptor Sr35 (Sr3527) and a single-chain antibody scFvM1 or scFv16 are fused to create an immune receptor-single-chain antibody fusion protein, and the immune receptor-single-chain antibody fusion protein can specifically recognize PVY coat protein (CP) or CP of ToBRFV, activate host resistance and generate hypersensitive response (HR); after being expressed in plants, the bacillus subtilis can inhibit infection of PVY or ToBRFV, and has a remarkable prevention and treatment effect on PVY or ToBRFV.

Provided is novel use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite, or prodrug thereof in preventing or treating hypersensitivity or autoimmune inflammation-related disorder.

The application provides a kind of low sensitization of penaeus vannamei and its preparation method and application, belong to food biotechnology field.The application uses fucoidan to treat penaeus vannamei by covalent modification, after treatment, protein spatial conformation has changed significantly, allergen epitope is hidden.After BALB / c mouse sensitization model and RBL-2H3 cell degranulation model test shows, the sensitization of covalent modification penaeus vannamei decreases by 72.88%, low sensitization penaeus vannamei can inhibit mast cell degranulation and increase the threshold of sensitization, but still has immunogenicity.Through the construction of BALB / c mouse oral tolerance model, it is found that low sensitization penaeus vannamei can significantly alleviate the multiple immunoglobulin-mediated hypersensitivity caused by mouse allergy, which proves that low sensitization penaeus vannamei has auxiliary effect on oral tolerance, can promote oral tolerance ability, can be used as an effective immune tolerance agent for shrimp allergy patients.

The application discloses application of TPPP3 as an action target in preparation of a type I hypersensitivity reaction drug, and belongs to the technical field of biological medicine preparation.The application discloses application of an inhibitor of TPPP3 in preparation of a type I hypersensitivity reaction drug, wherein the inhibitor comprises siRNA interfering with gene expression of TPPP3 and / or Indibulin.The application knocks down the TPPP3 gene through RNAi technology, finds that deletion of the TPPP3 gene can significantly inhibit IgE-mediated mast cell degranulation, and reduces activity of an upstream signal molecule of an Fc epsilon RI signal pathway to regulate the type I hypersensitivity reaction, and also finds that Indibulin can inhibit RBL-2H3 cell degranulation in vitro, and can inhibit a PCA reaction in a mouse in vivo, indicating that the Indibulin has a treatment potential for type I hypersensitivity reaction diseases.